ArticleRSC advances2019
Synthesis, optical, electrochemical properties and anticancer activity of (S)-BINOL cored triazole bridged dendrimers decorated with rhodamine B surface group.
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review of photoresponsive and glycoside dendrimers in biomaterials and sensors applications.RSC advances · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(S)-BINOL cored dendrimers 1-3 with a rhodamine B surface group and triazole bridging unit were synthesized up to second generation in good yield by convergent synthesis through click chemistry. The chiro-optical property of the synthesized dendrimers reveals that the specific rotation increases as the order of dendrimer increases from the zeroth generation to the second generation dendrimer. The electrochemical properties of the dendrimers 1, 2 and 3 showed quasi-reversible behavior in cyclic voltammetry. The anticancer activity against human hepatocellular carcinoma cell for the second generation dendrimer 3 was found to be better than that for the lower generation dendrimers 1 and 2.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.